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Abstract
Background: Guidelines for general hypertension treatment do not recommend the combined use of renin-
angiotensin-aldosterone system (RAAS) inhibitors due to the risk of hyperkalemia. However, a recent clinical trial
showed that polycystic kidney disease (PKD) patients had infrequent episodes of hyperkalemia despite receiving
combined RAAS inhibitors. Because intrarenal RAAS is a main component for renal potassium handling, we further
investigated the association between intrarenal RAAS activity and serum potassium level in patients with chronic
kidney disease, particularly in PKD patients, and examined whether intrarenal RAAS activity has a prognostic role in
patients with PKD.
Methods: A total of 1788 subjects from the KoreaN cohort study for Outcome in patients With Chronic Kidney
Disease (KNOW-CKD) were enrolled in this study. Intrarenal RAAS activity was assessed by the measurement of urinary
angiotensinogen (AGT). The primary outcome was the composite of all-cause mortality and renal function decline.
Results: Patients with PKD had a significantly lower serum potassium level in chronic kidney disease stages 1 to 3b
than non-PKD patients. In logistic regression analysis, after adjusting for multiple confounders, PKD patients had a
significantly lower risk of hyperkalemia than non-PKD patients. In multivariable linear regression analysis, the urinary
AGT/creatinine (Cr) ratio was negatively correlated with the serum potassium level (β = − 0.058, P = 0.017) and positively
correlated with the transtubular potassium gradient (TTKG, β = 0.087, P = 0.001). In propensity score matching analysis,
after matching factors associated with serum potassium and TTKG, PKD patients had a significantly higher TTKG
(P = 0.021) despite a lower serum potassium level (P = 0.004). Additionally, the urinary AGT/Cr ratio was significantly higher
in PKD patients than in non-PKD patients (P = 0.011). In 293 patients with PKD, high urinary AGT/Cr ratio was associated
with increased risk of the composite outcome (hazard ratio 1.29; 95% confidence interval, 1.07–1.55; P = 0.007).
Conclusions: High activity of intrarenal RAAS is associated with increased urinary potassium excretion and low serum
potassium level in patients with PKD. In addition, intrarenal RAAS activity can be a prognostic marker for mortality and
renal function decline in these patients.
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Background
Polycystic kidney disease (PKD) is a genetic disorder
characterized by a progressively increasing number of
fluid-filled cysts, distortion of the normal kidney struc-
ture, and loss of renal function over a period of decades
[1]. Early-onset hypertension is one of the key features
in PKD, and up to 80% of patients are diagnosed as hav-
ing hypertension before significant renal dysfunction [2].
In addition, hypertension is associated with a larger kid-
ney volume, progression to end-stage renal disease, and
cardiovascular mortality in patients with PKD [3–5].
Although the pathophysiologic mechanism of hyperten-
sion has not been fully elucidated in PKD, it is generally
accepted that the renin-angiotensin-aldosterone system
(RAAS) plays a pivotal role [6, 7]. Moreover, RAAS is
known to be one of the main contributors to the pro-
gression of chronic kidney disease (CKD). Numerous
clinical trials have demonstrated that RAAS inhibition
by an angiotensin-converting enzyme inhibitor (ACEi)
or angiotensin-II receptor blocker (ARB) prevents the
progression of CKD [8–11]. Thus, it was expected that
dual inhibition using an ACEi and ARB would be more
effective in inhibiting the progression of CKD; however,
three randomized controlled trials have failed to demon-
strate this [12–14]. In contrast, these trials demonstrated
that dual inhibition significantly increased the incidence
of hyperkalemia and renal impairment. Furthermore,
two of the trials involving dual RAAS inhibition in pa-
tients with type 2 diabetes mellitus (DM) were termi-
nated early because of an increased risk of hyperkalemia
and acute kidney injury [13, 14].
Recently, the effect of dual RAAS inhibition in pa-
tients with PKD using an ACEi and ARB was evalu-
ated in large randomized controlled trials (the HALT
Progression of Polycystic Kidney Disease (HALT-PKD)
studies) [15, 16]. These studies confirmed that redu-
cing blood pressure is effective in reducing protein-
uria and slowing the rate of total kidney volume
increase. Interestingly, adverse events including hyper-
kalemia and acute kidney injury were infrequent and
not different between the dual and single RAAS in-
hibition groups.
The potassium concentration in extracellular fluid is
regulated within a narrow range by the kidney, the pri-
mary organ of this homeostatic system. Augmented activ-
ity of the RAAS increases sodium reabsorption in the
kidney, which induces the electrochemical gradient for
potassium to pass into the lumen in the distal convoluted
tubule and collecting duct, enhancing potassium excretion
[17]. Therefore in this study, we aimed to evaluate potas-
sium regulation in patients with CKD due to PKD and
other etiologies by analyzing the activity of the intrarenal
RAAS and consequent tubular potassium secretion. Since
urinary angiotensinogen (AGT) has been used as a
valuable biomarker for estimating the intrarenal RAAS in
patients with CKD [18], we compared the relationship be-
tween urinary AGT and serum potassium levels among
patients with various etiologies of CKD. Furthermore, we
investigated the role of urinary AGT as a prognostic
marker in patients with PKD.
Methods
Study design and population
We utilized data from the KoreaN cohort study for
Outcome in patients With Chronic Kidney Disease
(KNOW-CKD), a nationwide, multi-center, prospect-
ive cohort study to clarify the natural course, compli-
cation profiles, and risk factors of Asian populations
with CKD. The detailed design and methods of the
study have been described previously [19] (ID no.
NCT01630486, http://www.clinicaltrials.gov). Briefly,
2341 individuals aged 20 to 75 years with CKD stages
1 to 5 without dialysis who voluntarily provided in-
formed consent were recruited between 2011 and
2015 from 9 clinical centers. Exclusion criteria were as
follows: 1) individuals unable or unwilling to give writ-
ten consent, 2) individuals who previously received
chronic dialysis or organ transplantation, 3) individ-
uals with heart failure (New York Heart Association
class III or IV), 4) individuals with liver cirrhosis
(Child-Pugh class 2 or 3), 4) individuals with a past or
current history of malignancy, 5) pregnant individuals,
and 6) individuals with a single kidney due to trauma
or kidney donation. After excluding 103 patients who
did not meet the inclusion criteria or had missing data
for isotope dilution mass spectrometry (IDMS)-cali-
brated creatinine (Cr), 2238 participants were in-
cluded. For this study, we additionally excluded 158
patients without data for urinary AGT levels. Further-
more, to ensure correct calculation of the transtubular
potassium gradient (TTKG), we excluded another 292 pa-
tients with random urine sodium less than 25mmol/L and
those with urine osmolality less than the plasma osmolality
[20]. Finally, 1788 patients were included in the analysis.
We first analyzed the relationship between urinary AGT
and serum potassium level according to etiology of CKD in
1788 patients (Fig. 1). In addition, we conducted a longitu-
dinal analysis in 293 PKD patients to evaluate the impact of
urinary AGT level on outcome in this group. This study
was carried out in accordance with the Declaration of
Helsinki, and the study protocol was approved by the re-
spective institutional review boards of the participating
centers, including Seoul National University Hospital,
Yonsei University Severance Hospital, Kangbuk Samsung
Medical Center, Seoul St. Mary’s Hospital, Gil Hospital,
Eulji General Hospital, Chonnam National University
Hospital, and Busan Paik Hospital.
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Data collection
Baseline sociodemographic data were retrieved from the
electronic data management system of the KNOW-CKD
developed by the Seoul National University Medical Re-
search Collaborating Center. Anthropometric measure-
ments, including height and weight, were obtained at
the baseline visit, and blood pressure was measured
using an electronic sphygmomanometer by a trained
nurse in the clinic. Blood and first-voided urine samples
were sent to the central laboratory of the KNOW-CKD
(Lab Genomics, Seongnam, Republic of Korea) by stand-
ard protocol. The serum Cr level was measured by using
the IDMS-traceable method, and estimated glomerular
filtration rate (eGFR) was calculated with the CKD Epi-
demiology Collaboration equation [21]. The urinary
AGT level was measured by using an enzyme-linked im-
munosorbent assay kit (IBL International GmBH, Ham-
burg, Germany). Intra-assay and inter-assay coefficients
of variation were less than 5.5 and 5.8%, respectively.
The TTKG was calculated by using the following for-
mula: (urine potassium level/serum potassium level)/
(urine osmolality/serum osmolality) [22]. Hyperkalemia
was defined as a serum potassium level greater than
5.0 mmol/L.
Clinical outcome
The primary outcome of this study was the composite of
all-cause mortality and renal function decline. Renal
function decline was defined as a > 50% decline of the
eGFR from baseline, doubling of the serum creatinine
level, or the initiation of dialysis (hemodialysis or peri-
toneal dialysis).
Statistical analyses
All subjects were categorized into 5 groups according to
the etiology of CKD: diabetic nephropathy (DN), hyperten-
sive nephrosclerosis (HTN), glomerulonephritis (GN), poly-
cystic kidney disease (PKD), and unclassified. Continuous
variables between groups were compared using one-way
analysis of variance, and post-hoc analyses between groups
were conducted with Bonferroni analysis. Nonparametric
variables were compared using the Kruskal-Wallis test, and
categorical variables were compared using the chi-square
test. The risks of hyperkalemia among CKD patients
grouped by etiology were compared using multivariable
logistic regression analysis. To evaluate the relationship
between the urinary AGT/Cr ratio and serum potassium
level or TTKG, multivariable linear regression analyses
were conducted, and the selection of covariables was done
using the stepwise method. In addition, to minimize the
effects of comorbidities, kidney function, and other labora-
tory findings, propensity score matching (PSM) was used.
Propensity scores were estimated using logistic regression
with the nearest neighbor technique without replacement,
and a predefined caliper of 0.2 times the standard deviation.
The covariables shown to be associated with the serum
Total 2238 patients who included in the KNOW-CKD study; CKD 
stage 1-5 (pre-dialysis)
Excluded 
-158 patients without data 
of urinary AGT levels
- 292 patients with UNa < 25 
mmol/L
2nd longitudinal analysis : the 
relationship between urinary 
AGT/Cr ratio and composite 
outcome in 293 PKD patients
1788 patients included for the study
1st cross-sectional analysis : 
the relationship between 
urinary AGT/Cr ratio and 
serum potassium levels 
(293 PKD patients vs. 1495 
non-PKD patients)
Fig. 1 Flow chart for patient enrollment and analyses
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potassium level and TTKG in multivariable linear regres-
sion analysis were used for the matching. The PKD group
was matched with the non-PKD group at a ratio of 1:1.
In these matched cohorts, comparisons between groups
were conducted with the paired t-test, McNemar’s test,
and Wilcoxon signed-rank test, as appropriate. Finally,
we conducted multivariable Cox regression analysis to
determine whether the AGT/Cr ratio was a prognostic
factor of composite outcome in all 293 patients with
PKD. We further categorized patients into 2 groups
according to the median value of AGT/Cr ratio, and
delineated the cumulative hazard of composite outcome
in them using the multivariable Cox regression model.
Statistical significance was defined as P < 0.05. All statis-
tical analyses were conducted by using SPSS software, ver-
sion 23.0 with Essentials for R Plug-in (IBM Corporation,
Armonk, NY, USA).
Results
Baseline characteristics
The baseline characteristics of patients according to
the etiology of CKD are presented in Table 1. Pa-
tients’ mean age was 54 ± 12.2 years, and 38.6% were
women. The mean age was significantly lower in the
PKD group than in the other groups. The prevalence
rates of hypertension and DM were significantly
lower in the PKD group than in the other groups
(P < 0.001, all). The mean creatinine level and eGFR
were 1.8 mg/dL and 50.1 mL/min/1.73 m2, respect-
ively. The mean eGFR was significantly higher in the
PKD group than in the other groups (P < 0.001, all).
The median urinary AGT/Cr ratio was 32.5, and it
was not significantly different between the groups.
However, the mean serum potassium level in the
PKD group was 4.4 ± 0.4 mmol/L, which was lower
than that of the other groups (P < 0.001, all). In
addition, the mean TTKG was significantly higher in
the PKD group than in the other groups (P < 0.001,
all). Fewer patients in the PKD group received any
RAAS inhibition than the DN (P = 0.001) and GN
(P < 0.001) groups, and fewer patients in the PKD
group received dual RAAS inhibition than the others
as well. The PKD group also had a smaller number
of patients who received diuretics compared to the
other groups (P < 0.001, all).
Risk of hyperkalemia among CKD groups
When we compared serum potassium levels for each
CKD stage, the PKD group had a lower serum potassium
level in CKD stages 1 to 3 than the non-PKD group
(Fig. 2). The prevalence of hyperkalemia was also lower
in the PKD group than in the other CKD groups up to
CKD stage 3 (K > 5.0) and stage 4 (K > 5.5). In the other
stages it is similar to all except DN (K > 5.0) or HTN
(K > 5.5) (Fig. 3). The lower prevalence of hyperkalemia
in PKD was prominent in the early CKD stages, and
attenuated with decline of renal function. In the multivari-
able logistic regression analysis, we built up consecutive
multi-step models. First, we adjusted for age, sex, history
of DM, body mass index (BMI), and systolic blood pres-
sure (SBP) in model 1, and found that the risk of hyperka-
lemia was significantly lower in the PKD group than in
the other CKD groups (Table 2). In model 2, we further
adjusted for laboratory parameters including serum so-
dium and urinary protein-to-creatinine ratio (UPCR);
use of anti-hypertensive medications (RAAS inhibition,
diuretic, calcium channel blocker, and beta blocker)
was then additionally adjusted for in model 3. Signifi-
cantly lower risk of hyperkalemia in PKD was persistent
in all models.
Urinary AGT/Cr ratio was correlated with the serum
potassium level and TTKG
To evaluate the association between intrarenal RAAS
activity and the serum potassium level, multivariable
linear regression analyses were conducted (Table 3). In
these analyses, a history of DM, BMI, eGFR, total car-
bon dioxide (CO2) level, serum albumin level, UPCR,
urine osmolality, and use of diuretics were signifi-
cantly correlated with the serum potassium level. In
addition, the eGFR, total CO2 level, urine osmolality,
age, sex, and Charlson comorbidity index (CCI) were
associated with TTKG. The urinary AGT/Cr ratio was
negatively correlated with the serum potassium level
(β = − 0.058, P = 0.017) and positively correlated with
TTKG (β = 0.087, P = 0.001).
Values of urinary AGT/Cr ratio, serum potassium, and
TTKG after PSM
To minimize the effect of confounders, PSM was per-
formed. The matching was conducted with covariables, in-
cluding age, sex, CCI, DM, BMI, eGFR, total CO2 level,
serum albumin level, UPCR, urine osmolality, and use of
diuretics, which were shown to be associated with the
serum potassium level and TTKG. After matching patients
in the PKD group with those in the non-PKD group, 196
patients remained in each group (Table 4). In this matched
cohort, patients in the PKD group had a significantly lower
serum potassium level (P = 0.004) than the non-PKD group,
whereas the serum sodium (P = 0.007) and chloride (P =
0.002) levels were higher in the PKD group than in the
non-PKD group. Interestingly, the TTKG was significantly
higher in the PKD group (P = 0.021), which means that
urinary excretion of potassium was larger despite lower
serum potassium levels in the PKD group. Moreover, the
percentage of patients who received RAAS inhibition was
not different between groups in the matched cohort,
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however, patients in the PKD group had a significantly
higher urinary AGT/Cr ratio (P = 0.011).
Urinary AGT/Cr ratio as a prognostic marker in patients
with PKD
To examine the role of the urinary AGT/Cr ratio as
a prognostic factor in the PKD group, we conducted
multivariable Cox regression analyses (Table 5). Dur-
ing the median follow-up of 4.6 years, 37 (12.6%)
composite events (all-cause mortality and renal func-
tion decline) occurred. After adjusting for multiple
covariables, the urinary AGT/Cr ratio was a signifi-
cant risk factor for the composite outcome (hazard
ratio (HR) 1.29; 95% confidence interval (CI), 1.07–
1.55; P = 0.007). When we stratified patients into two
groups according to the median value of the urinary
AGT/Cr ratio of 30.5, those in the high urinary
AGT/Cr ratio group had a significantly higher
cumulative hazard of the composite outcome (HR
2.26; 95% CI, 1.10–4.65; P = 0.026; Fig. 4).
Discussion
In this study, we demonstrated that the risk of hyper-
kalemia was significantly lower in patients with PKD
than in patients with other etiologies of CKD. In
addition, the urinary AGT/Cr ratio was associated with
TTKG as well as the serum potassium level. By using
PSM analysis, we found that patients with PKD had a
significantly lower serum potassium level and a higher
urinary AGT/Cr ratio and TTKG when compared to
patients without PKD. Therefore, it can be presumed
that high activity of intrarenal RAAS causes larger
urinary potassium excretion which leads to lower
serum potassium levels in patients with PKD. Further-
more, the urinary AGT/Cr ratio was a significant risk
0
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Fig. 3 Prevalence of hyperkalemia according to etiology of CKD in each CKD stage. a serum potassium level > 5.0 mmol/L, (b) serum
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Fig. 2 Serum potassium levels in each CKD stage. * P < 0.05
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factor of all-cause mortality and decline in renal func-
tion in patients with PKD.
It has been widely accepted that increased RAAS ac-
tivity is a central physiologic mechanism for the devel-
opment of hypertension in patients with PKD, and
recent studies have focused further on its role in patients
with PKD. Among several intrarenal RAAS components,
the urinary AGT level has been shown to be correlated
with the intrarenal activities of AGT and angiotensin II
[23, 24]. In addition, the urinary AGT/Cr ratio was in-
versely correlated with the eGFR and positively correlated
with the height-adjusted total kidney volume in patients
with PKD [25]. Kocyigit et al. also found that the urinary
AGT/Cr ratio was significantly associated with SBP [26],
and reported that it was higher in hypertensive patients
with PKD than healthy controls. A recent study by Salih
et al. compared circulating and urinary RAAS compo-
nents between patients with PKD and those with CKD
but without PKD [27]; after adjusting for sex, eGFR, blood
pressure, and RAAS inhibitor use between groups, the
urinary AGT level and renin excretion were 5- to 6-fold
higher in PKD than non-PKD patients, whereas circulat-
ing levels were not different. This was consistent with the
findings in our study. There have been several possible
explanations to explain why patients with PKD have
increased urinary RAAS activity. One is renin synthesis by
the cyst epithelium and dilated tubules [28]. Another is
that other components of RAAS, including AGT, angio-
tensin converting enzyme (ACE), and angiotensin II can
be produced within cysts and several parts of the tubules
[29]. In addition, because renin and AGT are reabsorbed
by a megalin-dependent pathway in the proximal tubule
[30, 31], the functional defect in the proximal tubule in
PKD can lead to increased concentration of tubular renin
and angiotensinogen. Considering that ACE is abundant
in the proximal tubular brush border, the highly concen-
trated tubular renin and angiotensinogen can be easily
converted to angiotensin I and II [32]. Moreover, aug-
mented intrarenal RAAS activities are associated with
chronic inflammation and fibrotic change in the kidney,
which can lead to progressive renal injury [33, 34]. Ac-
cordingly, previous studies showed that urinary AGT was
associated with the development and progression of CKD
[18, 35]. In our study, we also showed that urinary AGT/
Cr ratio was correlated with decline in renal function and
mortality in patients with PKD. To our knowledge, this is
the first longitudinal study that has shown urinary AGT as
a prognostic marker in patients with PKD.
Of note, we additionally found that the AGT/Cr ratio
was negatively correlated with serum potassium level
and positively correlated with TTKG. In our PSM ana-
lysis, the TTKG was paradoxically elevated in patients
Table 3 Multivariate linear regression analyses for the
relationship between serum potassium, transtubular potassium
gradient, and urine angiotensinogen-creatinine ratio
Variables Dependent variables
Serum potassium TTKG
β p-value β p-value
DM (vs. non-DM) 0.171 < 0.001 – –
BMI (kg/m2) −0.047 0.044 – –
eGFR (mL/min/1. 73m2) −0.315 < 0.001 0.157 < 0.001
Total CO2 (mmol/L) −0.152 < 0.001 0.174 < 0.001
Serum albumin (g/dL) 0.066 0.019 – –
UPCR (g/g)* 0.120 < 0.001 – –
Urine AGT/Cr ratio (μg/g)* − 0.058 0.017 0.087 0.001
Urine osmolality (mOsm/kg)* − 0.056 0.046 0.118 < 0.001
Diuretics (vs. non-user) – –
Age (years) – – 0.104 < 0.001
Sex (vs. female) – – 0.139 < 0.001
Charlson comorbidity index – – −1.000 0.002
β: Standardized coefficient
*Variables are log transformed
Abbreviations: TTKG, trans-tubular potassium gradient; DM, diabetes mellitus;
BMI, body mass index; eGFR, estimated glomerular filtration; CO2, carbon
dioxide; UPCR, urine protein-to-creatinine ratio;
AGT/Cr, angiotensinogen/creatinine
Table 2 Logistic regression analysis for the risk of hyperkalemia according to etiology of CKD
CKD subcohort Unadjusted Model 1 Model 2 Model 3
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
PKD (Reference) (Reference) (Reference) (Reference)
DN 9.52 (6.02–15.06) < 0.001 8.77 (4.74–16.24) < 0.001 4.65 (2.42–8.93) < 0.001 4.91 (2.54–9.50) < 0.001
HTN 3.42 (2.10–5.57) < 0.001 3.47 (2.07–5.83) < 0.001 2.54 (1.50–4.30) 0.001 2.57 (1.51–4.37) < 0.001
GN 2.79 (1.76–4.42) < 0.001 2.92 (1.82–4.66) < 0.001 1.70 (1.03–2.81) 0.038 1.82 (1.10–3.03) 0.02
Unclassified 4.57 (2.55–8.17) < 0.001 4.59 (2.44–8.65) < 0.001 2.86 (1.48–5.53) 0.002 2.95 (1.52–5.72) 0.001
Model 1: adjusted age, sex, history of DM, BMI, and SBP
Model 2: Model 1 + serum sodium and UPCR*
Model 3: Model 2 + use of RAAS blockade, diuretics, CCB, and beta blockers
*Data were log transformed
Abbreviations: CKD Chronic kidney disease, OR odds ratio, CI Confidence interval, PKD Polycystic kidney disease, DN Diabetic nephropathy, HTN Hypertensive
nephrosclerosis, GN, glomerulonephritis; eGFR, estimated glomerular filtration rate; BMI Body mass index; SBP, systolic blood pressure; UPCR, urine protein-to-
creatinine ratio; RAAS, renin-angiotensin-aldosterone system; CCB, calcium channel blocker
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with PKD, even though it should be lowered when the
serum potassium level is reduced. TTKG is positively as-
sociated with mineralocorticoid activity [36]. Lai et al.
previously reported that the prevalence of primary aldos-
teronism was 33% in patients with PKD, which was
greater than that in the general population [37].
Therefore, augmented intrarenal activities of angiotensin
II and aldosterone in PKD may lead to a lower serum
potassium level than that in other etiologies of CKD. In
the ONTARGET study, even though the mean creatinine
level of the participants was within normal range, the
combined use of telmisartan and ramipril was associated
with a higher incidence of hyperkalemia [38]. In
addition, combination treatment of losartan and lisino-
pril for patients with DM in CKD stages 2 and 3 was
stopped early in another study owing to safety concerns,
including hyperkalemia [13]. The combination of a dir-
ect renin inhibitor with other RAAS inhibitors also sig-
nificantly increased the risk of hyperkalemia [14]. As a
result, recent guidelines for hypertension do not recom-
mend combined use of RAAS inhibitors in general
hypertensive patients [39–41]. Furthermore, some re-
searchers have been concerned about an increased risk
of cancer with combination RAAS inhibitor therapy
[42]. However, when confined to PKD patients, even in
the study conducted for advanced PKD patients with an
eGFR less than 60mL/min/1.73 m2, episodes of hyperka-
lemia were infrequent, and cancer risk was not increased
[15]. Taking these results together, it can be suggested
that patients with PKD may have a lower risk of
Table 5 Multivariable Cox regression analysis for composite
outcome in patients with PKD
Variables Hazard
ratio
95% confidence
interval
p-value
Age (year) 1.00 0.96–1.04 0.964
Sex (vs. female) 0.72 0.34–1.51 0.383
Baseline eGFR (mL/min/1. 73m2) 0.91 0.88–0.93 < 0.001
SBP (vs. < 130 mmHg) 2.02 1.03–3.97 0.042
BMI (kg/m2) 0.96 0.86–1.06 0.387
Use of RAAS blocker (vs. non-user) 1.29 0.42–3.95 0.655
Macroalbuminuria (vs. normo-
or microalbuminuria)
1.40 0.56–3.48 0.468
Urine AGT/Cr ratio (μg/g)a 1.29 1.07–1.55 0.007
aVariable was log transformed
Abbreviations: eGFR, estimated glomerular filtration rate; SBP, systolic blood
pressure; BMI, body mass index; RAAS, renin-angiotensin-aldosterone;
AGT/Cr, angiotensinogen/creatinine
Table 4 Propensity score matching analysis between the PKD and the non-PKD
Variables Before PSM After PSM
Non-PKD
(N = 1495)
PKD
(N = 293)
p-value Non-PKD
(N = 196)
PKD
(N = 196)
p-value
Matched variables
Age (years) 55.3 ± 12.0 47.0 ± 10.9 < 0.001 49.6 ± 12.9 49.1 ± 11.1 0.66
Female (n, %) 542 (36.3) 148 (50.5) < 0.001 87 (44.4) 87 (44.4) > 0.999
Charlson comorbidity index 1.6 ± 1.3 1.4 ± 1.2 0.125 1.6 ± 1.3 1.4 ± 1.2 0.098
DM (n, %) 616 (41.2) 12 (4.1) < 0.001 22 (11.2) 11 (5.6) 0.068
BMI (kg/m2) 24.9 ± 3.4 23.6 ± 3.1 < 0.001 24.2 ± 3.7 24.1 ± 3.2 0.891
eGFR (mL/min/1. 73m2) 46.6 ± 27.6 68.1 ± 34.2 < 0.001 57.7 ± 29.7 59.1 ± 30.1 0.589
Total CO2 (mmol/L) 25.6 ± 3.7 26.6 ± 3.2 < 0.001 26.4 ± 3.2 26.3 ± 3.2 0.924
Serum albumin (g/dL) 4.1 ± 0.4 4.4 ± 0.3 < 0.001 4.3 ± 0.3 4.4 ± 0.3 0.39
UPCR (g/g)a 0.6 (0.2–1.9) 0.1 (0.0–0.2) < 0.001 0.1 (0.0–0.4) 0.1 (0.0–0.3) 0.099
Urine osmolality (mOsm/kg)a 510.4 ± 142.5 516.7 ± 156.2 0.499 513.3 ± 148.0 514.2 ± 160.8 0.845
Diuretics (n, %) 545 (36.5) 32 (10.9) < 0.001 29 (14.8) 26 (13.3) 0.663
Matching results
Sodium (mmol/L) 140.9 ± 2.4 141.1 ± 2.2 0.206 140.9 ± 2.2 141.5 ± 2.0 0.007
Chloride (mmol/L) 105.6 ± 3.7 105.6 ± 3.0 0.716 105.1 ± 3.4 106.1 ± 3.0 0.002
Potassium (mmol/L) 4.7 ± 0.6 4.4 ± 0.4 < 0.001 4.6 ± 0.5 4.4 ± 0.5 0.004
TTKG 6.2 ± 2.3 7.2 ± 2.8 < 0.001 6.5 ± 2.6 7.1 ± 2.4 0.021
Urine AGT/Cr ratio (μg/g)a 33.6 (8.6–157.4) 30.5 (12.5–82.7) 0.627 17.7 (8.2–63.1) 30.5 (13.0–109.5) 0.011
RAAS blockade (n, %) 1310 (87.7) 229 (78.2) < 0.001 167 (85.2) 162 (82.7) 0.492
aData are expressed as median and interquartile range. Comparison was done by Mann-Whitney U test before matching, and Wilcoxon signed-rank test
after matching
Abbreviations: PKD, polycystic kidney disease; PSM, propensity score matching; DM, diabetes mellitus; BMI, body mass index; eGFR, estimated glomerular filtration
rate; CO2, carbon dioxide; UPCR, urine protein-to-creatinine ratio; TTKG, transtubular potassium gradient; AGT/Cr, angiotensinogen/creatinine
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hyperkalemia than those with other etiologies of CKD.
Considering that the HALT-PKD investigators used a
dose-adjustment protocol of RAAS inhibitors to achieve
a specific blood pressure target, a higher degree of
RAAS inhibition may be beneficial for attenuating the
decline in renal function in PKD patients with a low risk
of hyperkalemia.
Some limitations of this study should be discussed. First,
we cannot confirm causality based on our cross-sectional
analyses. However, with the vigorous adjustment of cov-
ariables and diverse analyses in a large cohort, we found
that patients with PKD had a higher AGT/Cr ratio and a
lower serum potassium level than those with other etiolo-
gies of CKD. Second, our data did not encompass any par-
ameter of systemic RAAS activity. Systemic AGT is
produced and released into circulation by the liver. Since
the molecular weight of AGT is 52–64 kDa and it is nega-
tively charged (similar to albumin), it cannot be filtered in
the glomerulus of a healthy kidney [32]. However, in the
case of proteinuric patients, systemic AGT can be filtered
through the glomerular barrier; thus, the measured urin-
ary excretion of AGT may partially reflect hepatic produc-
tion and not purely intrarenally produced AGT.
Moreover, many experimental and clinical studies have re-
ported that the urinary AGT/Cr ratio was positively corre-
lated with proteinuria [18, 23, 26, 35]. Therefore, Jang et
al. previously investigated this concern in patients with
IgA nephropathy [43]. They reported that the intrarenal
compartment, and not the systemic pool, was the main
source of urinary AGT even in patients with overt pro-
teinuria. In our study, PSM was performed mostly in pa-
tients with microalbuminuria because the levels of UPCR
were significantly lower in patients with PKD than in
those with other etiologies of CKD. As the urinary AGT/
Cr ratio can be increased in patients with overt protein-
uria, further studies with a wide range of proteinuria are
warranted to evaluate the RAAS activity in various etiolo-
gies of CKD with several components of the RAAS. Third,
nutritional indices, including potassium intake, were not
considered in our analyses. Low potassium intake is usu-
ally recommended for patients with CKD to avoid hyper-
kalemia in clinical practice, but it is also associated with
high blood pressure and CKD progression [44, 45]. We
did not include 24-h urinary potassium excretion in the
analyses because it was measured only in 831 (46.5%) pa-
tients. However, when we compared 24-h urinary potas-
sium excretion after PSM, the levels were not different
between the PKD and non-PKD groups (data not shown).
Conclusions
In conclusion, patients with PKD had a significantly
lower serum potassium level than those with other
Fig. 4 Cox proportional hazards regression curves for composite outcome in two groups of urinary AGT/Cr ratio. Curves were derived by
adjustment of following covariables: age, sex, baseline eGFR, BMI, SBP (≥ 130mmHg or not), presence of macro-albuminuria, use of RAAS blocker
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etiologies of CKD. In PSM analysis, the urinary AGT/Cr
ratio and TTKG were higher in patients with PKD than
in those without PKD. In addition, the urinary AGT/Cr
ratio was a significant prognostic marker for all-cause
mortality or decline in renal function in patients with
PKD. Therefore, further use of dual RAAS inhibition
may be beneficial to reduce high intrarenal RAAS activ-
ity with a low risk of hyperkalemia in patients with PKD.
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